(Q35871928)

10 August 2017

1 reference

title

Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections (English)

1 reference

10 August 2017

main subject

gram-positive bacteria

0 references

author name string

Barry I Eisenstein

series ordinal

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

1159-1169

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

10 August 2017

1 reference

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

In vitro bactericidal activity of daptomycin against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Daptomycin: a novel agent for Gram-positive infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Once-daily dosing in dogs optimizes daptomycin safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Inhibition of membrane potential-dependent amino acid transport by daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Lipoteichoic acid as a target for antimicrobial action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Bacterial biofilms: a common cause of persistent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Effect of vancomycin and rifampicin on meticillin-resistant Staphylococcus aureus biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Resistance studies with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Bactericidal activity of daptomycin against vancomycin-resistantEnterococcus faecium in an in vitro pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

The changing epidemiology of Staphylococcus aureus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

Vancomycin therapy and the progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1159

10.1517/13543784.13.9.1159

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference